NDAINJECTIONINJECTABLE
Approved
Oct 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
INTRALIPID 10% (i.v. fat emulsion) by Fresenius Kabi is clinical pharmacology intralipid 10% is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. First approved in 1975.
Drug data last refreshed 15h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INTRALIPID 10% is an intravenous lipid emulsion approved in 1975 that provides essential fatty acids and energy substrate for parenteral nutrition patients. It is metabolized as an energy source and prevents essential fatty acid deficiency (EFAD) by clearing from the bloodstream similarly to natural chylomicrons.
LOE Approaching
Product approaching loss of exclusivity with mature market positioning; team focus likely shifting toward brand defense and cost management rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Intralipid 10% is metabolized and utilized as a source of energy causing an increase in heat production, decrease in respiratory quotient and increase in oxygen consumption. The infused fat particles are cleared from the blood stream in a manner thought to be comparable to the…
Pharmacologic Class:
Lipid Emulsion
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on INTRALIPID 10% offers exposure to hospital-based pharmaceutical operations, formulary management, and mature product defense strategies in the critical care/parenteral nutrition space. This role suits professionals focused on operational excellence, payer relations, and institutional sales rather than innovation or pipeline development.
Brand Manager
Worked on INTRALIPID 10% at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.